MX2021001376A - Carboxamidas como inhibidores de proteasa específicos de ubiquitina. - Google Patents
Carboxamidas como inhibidores de proteasa específicos de ubiquitina.Info
- Publication number
- MX2021001376A MX2021001376A MX2021001376A MX2021001376A MX2021001376A MX 2021001376 A MX2021001376 A MX 2021001376A MX 2021001376 A MX2021001376 A MX 2021001376A MX 2021001376 A MX2021001376 A MX 2021001376A MX 2021001376 A MX2021001376 A MX 2021001376A
- Authority
- MX
- Mexico
- Prior art keywords
- carboxamides
- ubiquitin
- protease inhibitors
- inhibitors
- specific protease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente descripción se refiere a moduladores, tales como inhibidores, de al menos una vía seleccionada de USP28 y USP25, composiciones farmacéuticas que comprenden los inhibidores, y métodos de uso de los inhibidores. Los moduladores, tales como inhibidores, de al menos una vía seleccionada de USP28 y USP25 pueden ser útiles en el tratamiento del cáncer, entre otras afecciones.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862716744P | 2018-08-09 | 2018-08-09 | |
PCT/US2018/046061 WO2019032863A1 (en) | 2017-08-11 | 2018-08-09 | CARBOXAMIDES USED AS UBIQUITIN SPECIFIC PROTEASE INHIBITORS |
US201962788204P | 2019-01-04 | 2019-01-04 | |
US201962805118P | 2019-02-13 | 2019-02-13 | |
PCT/US2019/045732 WO2020033707A1 (en) | 2018-08-09 | 2019-08-08 | Carboxamides as ubiquitin-specific protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021001376A true MX2021001376A (es) | 2021-06-23 |
Family
ID=69457770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021001376A MX2021001376A (es) | 2018-08-09 | 2019-08-08 | Carboxamidas como inhibidores de proteasa específicos de ubiquitina. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210323975A1 (es) |
EP (1) | EP3833661A1 (es) |
JP (1) | JP2021534123A (es) |
KR (1) | KR20210068010A (es) |
CN (1) | CN112867712A (es) |
AU (1) | AU2019319907A1 (es) |
BR (1) | BR112021002408A2 (es) |
CA (1) | CA3108676A1 (es) |
IL (1) | IL280486A (es) |
MA (1) | MA53275A (es) |
MX (1) | MX2021001376A (es) |
WO (1) | WO2020033707A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111909181B (zh) * | 2019-05-09 | 2023-02-07 | 杭州普济远成生物医药科技有限公司 | 一类泛素化特异性蛋白酶抑制剂及其制备方法与应用 |
CN111943879A (zh) * | 2020-08-03 | 2020-11-17 | 南通大学 | 一种(3s,4r)3-氨基-4(甲氧基甲基)吡咯烷-1-甲酸叔丁酯及其合成方法 |
CN112898314A (zh) * | 2020-11-06 | 2021-06-04 | 刘丽萍 | 去泛素化酶抑制剂的制备与应用 |
WO2023122298A1 (en) * | 2021-12-22 | 2023-06-29 | Stablix, Inc. | Protein stabilizing compounds containing usp28 and/or usp25 targeting ligands |
WO2023208174A1 (zh) * | 2022-04-28 | 2023-11-02 | 杭州普济远成生物医药科技有限公司 | 去泛素化酶抑制剂及其应用 |
WO2023208130A1 (zh) * | 2022-04-29 | 2023-11-02 | 江苏亚虹医药科技股份有限公司 | 嘧啶类化合物、其制备方法及其医药用途 |
CN115246842A (zh) * | 2022-06-15 | 2022-10-28 | 深圳湾实验室 | 一类靶向去泛素化酶usp25和usp28的小分子抑制剂 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050130974A1 (en) * | 2003-10-17 | 2005-06-16 | Rigel Pharmaceuticals, Inc. | Benzothiazole compositions and their use as ubiquitin ligase inhibitors |
AR075402A1 (es) * | 2009-02-13 | 2011-03-30 | Sanofi Aventis | Derivados heterociclicos oxigenados y/o nitrogenados de tetrahidronaftaleno, medicamentos que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad,entre otros. |
DE102012006884A1 (de) * | 2012-04-04 | 2013-10-10 | Merck Patent Gmbh | Cyclische Amide als MetAP-2 Inhibitoren |
EP3148971A4 (en) * | 2014-06-02 | 2017-10-25 | Pharmakea, Inc. | Deubiquitinase inhibitors |
AU2016322813B2 (en) * | 2015-09-14 | 2021-04-01 | Pfizer Inc. | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors |
RU2750151C2 (ru) * | 2015-11-20 | 2021-06-22 | Форма Терапьютикс, Инк. | Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1 |
AU2018316254B2 (en) * | 2017-08-11 | 2022-07-14 | Valo Health, Inc. | Carboxamides as ubiquitin-specific protease inhibitors |
-
2019
- 2019-08-08 US US17/266,026 patent/US20210323975A1/en active Pending
- 2019-08-08 MX MX2021001376A patent/MX2021001376A/es unknown
- 2019-08-08 EP EP19759791.7A patent/EP3833661A1/en active Pending
- 2019-08-08 AU AU2019319907A patent/AU2019319907A1/en active Pending
- 2019-08-08 KR KR1020217007070A patent/KR20210068010A/ko unknown
- 2019-08-08 CA CA3108676A patent/CA3108676A1/en active Pending
- 2019-08-08 MA MA053275A patent/MA53275A/fr unknown
- 2019-08-08 CN CN201980066884.1A patent/CN112867712A/zh active Pending
- 2019-08-08 JP JP2021506766A patent/JP2021534123A/ja active Pending
- 2019-08-08 BR BR112021002408-5A patent/BR112021002408A2/pt not_active Application Discontinuation
- 2019-08-08 WO PCT/US2019/045732 patent/WO2020033707A1/en active Application Filing
-
2021
- 2021-01-28 IL IL280486A patent/IL280486A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20210323975A1 (en) | 2021-10-21 |
AU2019319907A1 (en) | 2021-02-18 |
MA53275A (fr) | 2021-09-15 |
IL280486A (en) | 2021-03-25 |
CN112867712A (zh) | 2021-05-28 |
BR112021002408A2 (pt) | 2021-05-04 |
JP2021534123A (ja) | 2021-12-09 |
EP3833661A1 (en) | 2021-06-16 |
KR20210068010A (ko) | 2021-06-08 |
CA3108676A1 (en) | 2020-02-13 |
WO2020033707A1 (en) | 2020-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021001376A (es) | Carboxamidas como inhibidores de proteasa específicos de ubiquitina. | |
WO2019222112A8 (en) | Mcl-1 inhibitors | |
PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
MX2022004304A (es) | Agentes inductores de apoptosis. | |
SG11202011886TA (en) | PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF | |
CA2956871C (en) | Compounds active towards bromodomains | |
JOP20220083A1 (ar) | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr | |
MX2016016744A (es) | Inhibidores de ezh2 para tratar linfomas. | |
WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
PH12015502698A1 (en) | Dual selective pi3 delta and gamma kinase inhibitors | |
MX2022002946A (es) | Inhibidores de cdk y su uso como productos farmaceuticos. | |
MX2019001011A (es) | Compuestos farmaceuticos. | |
PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
MX2022014007A (es) | Compuestos como inhibidores de bcl-2. | |
EA201991447A1 (ru) | Снижение вязкости фармацевтических составов | |
MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
MX2016016039A (es) | Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización.. | |
MX2021008941A (es) | Moduladores gpr35. | |
EA202190455A1 (ru) | Карбоксамиды в качестве ингибиторов убиквитинспецифической протеазы | |
WO2017210527A8 (en) | Autotaxin inhibitors | |
MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. | |
LV15670A (lv) | Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori | |
MX2023005681A (es) | Composicion farmaceutica para el tratamiento contra el dolor agudo y cronico, que contiene polmacoxib y tramadol. |